HC Wainwright Reaffirms “Buy” Rating for Vigil Neuroscience (NASDAQ:VIGL)

HC Wainwright reissued their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a report published on Wednesday morning, Benzinga reports. The brokerage currently has a $17.00 target price on the stock. HC Wainwright also issued estimates for Vigil Neuroscience’s Q3 2024 earnings at ($0.52) EPS, Q4 2024 earnings at ($0.52) EPS, FY2025 earnings at ($2.05) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at $0.29 EPS and FY2028 earnings at $0.78 EPS.

Several other research firms have also issued reports on VIGL. JMP Securities reiterated a market outperform rating and set a $23.00 price objective on shares of Vigil Neuroscience in a research note on Thursday, April 18th. Wedbush reissued an outperform rating and set a $23.00 price target on shares of Vigil Neuroscience in a report on Thursday, July 11th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Vigil Neuroscience presently has an average rating of Moderate Buy and an average target price of $16.60.

Vigil Neuroscience Price Performance

Shares of VIGL stock opened at $3.49 on Wednesday. The stock has a market cap of $138.38 million, a P/E ratio of -1.65 and a beta of 2.00. The stock has a fifty day moving average price of $3.98 and a 200 day moving average price of $3.44. Vigil Neuroscience has a one year low of $2.47 and a one year high of $9.24.

Vigil Neuroscience (NASDAQ:VIGL) last posted its earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.02. Equities research analysts anticipate that Vigil Neuroscience will post -2.1 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Strs Ohio bought a new stake in shares of Vigil Neuroscience during the fourth quarter worth $27,000. Vanguard Group Inc. boosted its stake in shares of Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after purchasing an additional 95,276 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Vigil Neuroscience in the 2nd quarter valued at about $26,000. Renaissance Technologies LLC raised its stake in shares of Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after buying an additional 11,536 shares during the last quarter. Finally, Ensign Peak Advisors Inc raised its stake in shares of Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after buying an additional 166,442 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.